R

Active Director Director DIN 05299874
DIN 05299874 First appointment Jul 2012 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2012
Shareholding value •••• Premium profile

About Roshmitha

Data last updated:

Roshmitha is a Director at Inmed Remedies Private Limited (since 2012). The company operates in Chemicals. Inmed Remedies Private Limited reported revenue of ₹7.4 Lakh (FY 2020).

DIN 05299874
Primary Designation Director
Industry Chemicals
First Appointment 19 Jul 2012
Oldest Company Age 14 yrs
Largest company Inmed Remedies Private Limited · ₹7.4 Lakh (FY 2020)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Inmed Remedies Private Limited U24231KL2012PTC031686
Director19 Jul 20122012₹7.4 Lakh (FY 2020)Active

Board colleagues of Roshmitha

NameDINCompanyDesignation
Kinattinkara Veettil Rubeesh06863085Inmed Remedies Private LimitedDirector

Directorship timeline

Open interactive timeline →
Inmed Remedies Private Limited
Premium access

Shareholding and investment profile for Roshmitha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Roshmitha

Roshmitha currently holds 1 directorship: Inmed Remedies Private Limited (Director, since 19 Jul 2012, revenue ₹7.4 Lakh (FY 2020)).

Roshmitha was first appointed on 19 Jul 2012 as Director at Inmed Remedies Private Limited.

The current boards of Roshmitha's companies include Kinattinkara Veettil Rubeesh (Inmed Remedies Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available